Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

被引:21
作者
Tsao, Anne S. [1 ]
Moon, James [2 ]
Wistuba, Ignacio I. [3 ]
Vogelzang, Nicholas J. [4 ]
Kalemkerian, Gregory P. [5 ]
Redman, Mary W. [2 ]
Gandara, David R. [6 ]
Kelly, Karen [6 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] SWOG Stat Ctr, Seattle, WA USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA
[4] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[5] Univ Michigan, Ann Arbor, MI 48109 USA
[6] Univ Calif Davis, Canc Ctr, Sacramento, CA 95817 USA
基金
美国国家卫生研究院;
关键词
Mesothelioma; Cediranib; Cisplatin; Pemetrexed; IDIOPATHIC PULMONARY-FIBROSIS; ENDOTHELIAL GROWTH-FACTOR; IMATINIB MESYLATE; DOUBLE-BLIND; PLUS BEVACIZUMAB; FACTOR PDGF; FACTOR-BETA; EXPRESSION; RECEPTOR; PLACEBO;
D O I
10.1016/j.jtho.2017.05.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: In malignant pleural mesothelioma, targeting angiogenesis with cediranib, a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, may have therapeutic potential. Methods: S0905 phase I combined cediranib (two dose cohorts [30 mg and 20 mg daily]) with cisplatin-pemetrexed for six cycles followed by maintenance cediranib in unresectable chemonaive patients with malignant pleural mesothelioma of any histologic subtype. The primary end point established the maximum tolerated dose in combination with cisplatin-pemetrexed in a dose deescalation scheme. Results: A total of 20 patients were enrolled (seven to the 30-mg cohort and 13 to the 20-mag cohort). In the cediranib 30-mg cohort, two of the initial six patients reported dose-limiting toxicities and the dose was deemed too toxic to continue. In the next cohort, two patients experienced dose-limiting toxicities, and thus, the maximum tolerated dose of cediranib was established as 20 mg. During the six cycles of cisplatin-pemetrexed-cediranib, 20 mg, there were grade 3 toxicities (neutropenia and gastrointestinal) and grade 4 thrombocytopenia. No patients had any significant episodes of bleeding. According to the Response Evaluation Criteria in Solid Tumors (n = 17 evaluable patients), the median progression-free survival was 12.8 months (95% confidence interval [CI]: 6.9-17.2); according to the Modified Response Evaluation Criteria in Solid Tumors (n = 19 evaluable patients), the median progression-free survival was 8.6 months (95% CI: 6.1-10.9). For all patients, the disease control rate at 6 weeks was 90% and median overall survival time was 16.2 months (95% CI: 10.5-28.7). Conclusions: Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy. The phase II 50905 trial will evaluate the efficacy of the triplet regimen compared with the current standard of care, cisplatin-pemetrexed. (C) 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1299 / 1308
页数:10
相关论文
共 31 条
[1]   Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis [J].
Abdollahi, A ;
Li, ML ;
Ping, G ;
Plathow, C ;
Domhan, S ;
Kiessling, F ;
Lee, LB ;
McMahon, G ;
Gröne, HJ ;
Lipson, KE ;
Huber, PE .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (06) :925-935
[2]   Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts [J].
Bertino, Pietro ;
Piccardi, Federica ;
Porta, Camillo ;
Favoni, Roberto ;
Cilli, Michele ;
Mutti, Luciano ;
Gaudino, Giovanni .
CLINICAL CANCER RESEARCH, 2008, 14 (02) :541-548
[3]   Preliminary data suggestive of a novel translational approach to mesothelioma treatment: Imatinib mesylate with gemcitabine or pemetrexed [J].
Bertino, Pietro ;
Porta, Camillo ;
Barbone, Dario ;
Germano, Serena ;
Busacca, Sara ;
Pinato, Sabrina ;
Tassi, Giancarlo ;
Favoni, Roberto ;
Gaudino, Giovanni ;
Mutti, Luciano .
THORAX, 2007, 62 (08) :690-695
[4]   Mechanisms of TKI-induced diarrhea in cancer patients [J].
Bowen, Joanne M. .
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2013, 7 (02) :162-167
[5]   Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma [J].
Ceresoli, G. L. ;
Zucali, P. A. ;
Mencoboni, M. ;
Botta, M. ;
Grossi, F. ;
Cortinovis, D. ;
Zilembo, N. ;
Ripa, C. ;
Tiseo, M. ;
Favaretto, A. G. ;
Soto-Parra, H. ;
De Vincenzo, F. ;
Bruzzone, A. ;
Lorenzi, E. ;
Gianoncelli, L. ;
Ercoli, B. ;
Giordano, L. ;
Santoro, A. .
BRITISH JOURNAL OF CANCER, 2013, 109 (03) :552-558
[6]  
DORAI T, 1994, MOL PHARMACOL, V46, P437
[7]   A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma [J].
Dowell, Jonathan E. ;
Dunphy, Frank R. ;
Taub, Robert N. ;
Gerber, David E. ;
Ngov, Likheng ;
Yan, Jingsheng ;
Xie, Yang ;
Kindler, Hedy Lee .
LUNG CANCER, 2012, 77 (03) :567-571
[8]   Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms [J].
Erber, R ;
Thurnher, A ;
Katsen, AD ;
Groth, G ;
Kerger, H ;
Hammes, HP ;
Menger, MD ;
Ullrich, A ;
Vajkoczy, P .
FASEB JOURNAL, 2003, 17 (15) :338-340
[9]   Advances in the systemic therapy of malignant pleural mesothelioma [J].
Fennell, Dean A. ;
Gaudino, Giovanni ;
O'Byrne, Kenneth J. ;
Mutti, Luciano ;
van Meerbeeck, Jan .
NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (03) :136-147
[10]   Serum PDGF-AB in pleural mesothelioma [J].
Filiberti, R ;
Marroni, P ;
Neri, M ;
Ardizzoni, A ;
Betta, PG ;
Cafferata, MA ;
Canessa, PA ;
Puntoni, R ;
Ivaldi, GP ;
Paganuzzi, M .
TUMOR BIOLOGY, 2005, 26 (05) :221-226